Core Viewpoint - The company reported a revenue of 308 million yuan for the first half of 2025, reflecting a year-on-year increase of 3.79%, while the net profit attributable to shareholders reached 1 million yuan, up 103.63% year-on-year [1]. Financial Performance - The company achieved a revenue of 187 million yuan from industrial leak detection instruments, a year-on-year increase of 7.34%. Revenue from environmental monitoring instruments was 73 million yuan, down 17.59% year-on-year. Laboratory analysis instruments generated 26 million yuan, up 43.83% year-on-year, while other businesses contributed 21 million yuan, up 40.10% year-on-year [2]. - In Q2 2025, the company reported a revenue of 174 million yuan, a year-on-year decrease of 4.47% but a quarter-on-quarter increase of 29.30%. The net profit attributable to shareholders was 6 million yuan, up 36.74% year-on-year and 219.21% quarter-on-quarter [2]. - The gross profit margin for H1 2025 was 49.86%, an increase of 2.78 percentage points year-on-year. The Q2 gross profit margin was 49.73%, up 3.41 percentage points year-on-year but down 0.31 percentage points quarter-on-quarter [2]. Expense Management - The company’s expense ratio for H1 2025 was 53.28%, a decrease of 8.11 percentage points year-on-year. The sales, management, R&D, and financial expense ratios were 22.74%, 7.41%, 22.59%, and 0.55%, respectively, with year-on-year changes of -2.39, -1.51, -4.58, and +0.37 percentage points [3]. Business Development - The industrial detection instruments and solutions segment is focusing on product leadership in the new energy sector and exploring growth in semiconductors and overseas markets. A joint laboratory agreement was signed with Hefei Comprehensive National Science Center for collaborative research [4]. - The online monitoring instruments segment is transitioning towards digitalization, targeting pollution source and environmental monitoring opportunities in industries such as oil, chemicals, and steel [4]. - The laboratory analysis instruments segment is concentrating on drinking water testing and has made progress in earthquake system layouts, while also engaging in university equipment updates [4]. - In the medical instruments segment, the company has made significant advancements in minimally invasive surgical instruments and has successfully registered several medical devices [5]. International Expansion - The company has expanded its international presence, with products sold in over 20 countries and regions. An office has been established in Thailand, and a network of overseas distributors is being developed. Revenue from overseas business in H1 2025 was 8.72 million yuan, a year-on-year increase of 59.13% [6]. Future Outlook - Revenue forecasts for 2025-2027 have been adjusted, with expected revenues of 854 million, 1.02 billion, and 1.21 billion yuan, reflecting year-on-year growth rates of 15.4%, 19.4%, and 19.0%. Net profit forecasts for the same period are 59 million, 79 million, and 106 million yuan, with year-on-year growth rates of 307.5%, 35.3%, and 33.1% [7].

Group 1 - The company reported a revenue of 340 million yuan in 2024, a decrease of 6.7%, and a net profit attributable to shareholders of 100 million yuan, down 15.9% [2] - In Q1 2024, the company achieved a revenue of 66 million yuan, a decline of 11.2%, with a net profit of 11 million yuan, down 55.7% [2] - The gross margin improved to 70.4%, an increase of 0.7 percentage points, mainly due to the increased revenue share from surgical power consumables [2] Group 2 - The surgical power device equipment revenue declined significantly due to external factors affecting bidding, while consumables saw steady growth, increasing by 15.69% year-on-year [3] - The company is a leader in the domestic surgical power device market, continuously expanding into endoscopy and energy surgical equipment, aiming to become a comprehensive solution provider for surgical procedures [4] - The market for surgical power devices in China was valued at 7.2 billion yuan in 2022, with a trend towards single-use consumables gradually replacing reusable ones [4] Group 3 - The company expects a compound annual growth rate of 6.9% in net profit attributable to shareholders over the next three years, driven by the replacement of reusable consumables and the introduction of innovative products [5] - The company has made significant breakthroughs in the field of flexible endoscopy, successfully obtaining registration for new medical devices [4]